Pooled phase 3 trials show reduced OSA severity with oral drug over 26 weeks

ORLANDO — Among adults with mild to severe obstructive sleep apnea, those receiving AD109, an oral combination drug, vs. placebo achieved lower disease severity at 26 weeks, according to pooled phase 3 trial results presented here.AD109 (Apnimed) is made up of 2.5 mg aroxybutynin, a novel antimuscarinic, and 75 mg atomoxetine, a selective norepinephrine reuptake inhibitor, according to a